|Dr. Jan G. J. van de Winkel||Co-Founder, CEO & Pres||14.71M||N/A||1961|
|Mr. David A. Eatwell||Exec. VP & CFO||7.04M||N/A||1961|
|Dr. Judith Klimovsky||Exec. VP & Chief Devel. Officer||N/A||N/A||1958|
|Ms. Jane Juel||Sr. Director of Operations & Resource Management||N/A||N/A||N/A|
|Mr. Peter Ros||Sr. Director of Fin. & Accounting and R&D Operations||N/A||N/A||N/A|
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL, follicular lymphoma, and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, amyloidosis, and solid tumors; Tisotumab vedotin, HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; HuMax-TAC-ADC (ADCT-301) to treat lymphoma and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for metastatic solid tumors; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 for MM; and AMG 714 for the treatment of celiac disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Genmab A/S’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 6; Compensation: 9.